VVOS Stock Analysis: Buy, Sell, or Hold?
VVOS - Vivos Therapeutics, Inc. Common Stock
$0.40
-0.10 (-19.56%)
▼
5d:
-29.69%
30d:
-31.83%
90d:
-67.03%
HOLD
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When VVOS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: VVOS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: VVOS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: VVOS is currently trading at $0.40, which is considered oversold relative to its 30-day fair value range of $0.58 to $0.74.
Technical Outlook: Technically, VVOS is in a strong downtrend. The price is currently testing key support at $0.62. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 19.6% recently.
Market Sentiment: VVOS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $2.45 (+509.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VVOS is in a strong downtrend. The price is currently testing key support at $0.62. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 19.6% recently.
Market Sentiment: VVOS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $2.45 (+509.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.58 -
$0.74
Company Quality Score
45/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
47.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BEARISH: Downward momentum (-19.6%)
- BULLISH: Trading 509.1% below Wall St target ($2.45)
- CAUTION: 5-day price weakness (-29.7%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.58 -
$0.74
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.62
Resistance Level
$1.36
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.48
Wall Street Target
$2.45
(+509.1%)
Revenue Growth (YoY)
70.5%
Profit Margin
-127.7%
Share & Embed Analysis
Last updated: June 23, 2026 4:42 AM ET
Data refreshes hourly during market hours. Next update: 5:42 AM
Data refreshes hourly during market hours. Next update: 5:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VVOS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Michael C Skaff
BUY
1353625 shares
2026-03-31
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$77 | 52 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 61 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 59 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$242 | 60 HOLD |
